TLSATiziana Life Sciences Ltd

Nasdaq tizianalifesciences.com


$ 0.93 $ 0.00 (-0.37 %)    

Friday, 13-Sep-2024 15:35:25 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 0.9249
$ 0.93
$ 0.91 x 200
-- x --
$ 0.93 - $ 0.93
$ 0.41 - $ 1.74
39,551
na
95.35M
$ 0.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tiziana-life-sciences-appoints-ivor-elrifi-as-its-ceo-effective-immediately

Elrifi succeeds Gabriele Cerrone, who was acting CEO and will remain in his role as Executive Chairman of the board and will co...

Core News & Articles

TSLANVDAWAYAITLRYQQQAAPLAVGOSMCIAMZNData from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment 

 tiziana-life-sciences-reports-six-month-qualitative-results-for-all-10-non-active-secondary-progressive-multiple-sclerosis-patients-enrolled-in-intermediate-size-patient-population-expanded-access-program

Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded A...

 tiziana-life-sciences-reports-3-month-neuroimaging-scores-in-multiple-sclerosis-patients-receiving-intranasal-foralumab-a-primary-endpoint-with-clinical-measures-of-edss-disability-and-mfis-fatigue-is-currently-underway

Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing brea...

 tiziana-life-sciences-announces-fda-allowance-for-additional-patients-to-be-enrolled-in-intranasal-foralumab-multiple-sclerosis-expanded-access-program

Program to expand from 10 patients to a total of 30 patients.

 tiziana-life-sciences-announces-additional-clinical-improvements-among-multiple-sclerosis-patients-in-its-expanded-access-program

Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing brea...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION